Carbohydrates represent the most abundant class of molecules in nature and are involved in inflammation, cancer, and infectious disease. Consequently, the design of molecules that mimic structural features of carbohydrates but have improved drug-like properties such as increased affinity, serum half-life, stability, and bioavailability has gained growing attention over recent years. In this webinar the application and current limitations of computational methods that can support the design of glycomimetic inhibitors are discussed and some success stories are presented.
